Annotation Detail for CX3CR1

Basic Information
Top
Pathway ID | Pathway Name |
---|
hsa04062 | Chemokine signaling pathway |
hsa04060 | Cytokine-cytokine receptor interaction |
Pathway ID | Pathway Name |
---|
| Signaling by GPCR |
Pathway ID | Pathway Name |
---|
P00031 | Inflammation mediated by chemokine and cytokine signaling pathway |
Desease Name |
---|
Acute Coronary Syndrome |
cardiovascular disease |
restenosis |
Atherosclerosis |
atherosclerosis, coronary |
CARDIOVASCULAR |
Coronary Artery Disease |
Human Renal Transplantation |
CANCER |
coronary artery disease, occlusive |
Intestinal Obstruction |
RENAL |
Glioblastoma |
IMMUNE |
retinal vascular occlusion |
coronary vascular endothelial dysfunction |
VISION |
HIV |
pulmonary arterial hypertension sclerosis, systemic |
cerebrovascular disease |
INFECTION |
intima-media thickness |
Crohn Disease |
respiratory syncytial virus |
Desease Name |
---|
Coronary artery disease, resistance to |
Macular degeneration, age-related, susceptibility to |
Rapid progression to AIDS from HIV1 infection |
Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
---|
D000643 |
Ammonium Chloride |
Ammonium Chloride affects the expression of CX3CR1 mRNA | affects expression | 16483693
|
D002794 |
Choline |
Choline affects the expression of CX3CR1 mRNA | affects expression | 17616785
|
D003520 |
Cyclophosphamide |
Cyclophosphamide results in increased expression of CX3CR1 protein | increases expression | 16651033
|
D010972 |
Platelet Activating Factor |
Platelet Activating Factor results in increased expression of CX3CR1 mRNA | increases expression | 16386258
|
C025299 |
polyphenols |
polyphenols results in decreased expression of CX3CR1 mRNA | decreases expression | 16293270
|
D018038 |
Sodium Selenite |
Sodium Selenite results in decreased expression of CX3CR1 mRNA | decreases expression | 18175754
|
C066075 |
vanadium pentoxide |
vanadium pentoxide results in increased expression of CX3CR1 mRNA | increases expression | 17459161
|
Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
---|
MESH:D000138 |
Acidosis |
|
Ammonium Chloride |
3.95 | 18287403 |
MESH:D000741 |
Anemia, Aplastic |
marker/mechanism |
|
| 18575777 |
MESH:D001161 |
Arteriosclerosis |
|
Cyclophosphamide |
4.96 | 15014928 |
MESH:D001321 |
Autistic Disorder |
|
Choline |
3.33 | 16818868 |
MESH:D001943 |
Breast Neoplasms |
|
Cyclophosphamide |
2.96 | 17020986 11325840 15136595 17388661 16978400 18323546 15093573 18234424 12006526 |
MESH:D001991 |
Bronchitis |
|
vanadium pentoxide |
6.68 | 17459161 |
MESH:D006528 |
Carcinoma, Hepatocellular |
|
Cyclophosphamide |
2.63 | 19701751 |
MESH:D018827 |
Carcinoma, Lewis Lung |
|
Cyclophosphamide |
5.28 | 16152834 |
MESH:D002292 |
Carcinoma, Renal Cell |
|
Cyclophosphamide |
3.65 | 16201981 |
MESH:D054506 |
Chloracne |
marker/mechanism |
|
| 17101203 |
MESH:D019457 |
Chromosome Breakage |
|
Sodium Selenite |
5.11 | 15894690 |
MESH:D003110 |
Colonic Neoplasms |
|
polyphenols |
2.71 | 16293270 |
MESH:D003327 |
Coronary Disease |
marker/mechanism |
|
| |
MESH:D003556 |
Cystitis |
|
Cyclophosphamide |
5.43 | 18483878 16614059 18372110 15276878 17979934 10498854 16413132 18093676 10700343 15643279 12388444 12161096 11948286 18710439 16989017 16651033 18295254 12913760 17010015 18433785 |
MESH:D002658 |
Developmental Disabilities |
|
Choline |
4.85 | 16818868 |
MESH:D003920 |
Diabetes Mellitus |
|
Sodium Selenite |
4.03 | 16285004 |
MESH:D003921 |
Diabetes Mellitus, Experimental |
|
Cyclophosphamide |
4.30 | 15331540 10990075 11751995 |
MESH:D003922 |
Diabetes Mellitus, Type 1 |
|
Cyclophosphamide |
3.29 | 18772604 |
MESH:D056486 |
Drug-Induced Liver Injury |
|
polyphenols |
4.48 | 19370779 |
MESH:D056486 |
Drug-Induced Liver Injury |
|
Sodium Selenite |
4.48 | 15131321 |
MESH:D004802 |
Eosinophilia |
|
Cyclophosphamide |
4.57 | 11006010 |
MESH:D018316 |
Gliosarcoma |
|
Cyclophosphamide |
5.91 | 11389073 |
MESH:D006086 |
Graft vs Host Disease |
|
Cyclophosphamide |
5.39 | 16376943 15172196 11014644 |
MESH:D006467 |
Hemophilia A |
|
Cyclophosphamide |
5.65 | 11918545 |
MESH:D006504 |
Hepatic Veno-Occlusive Disease |
|
Cyclophosphamide |
5.98 | 14986274 |
MESH:D006689 |
Hodgkin Disease |
|
Cyclophosphamide |
4.03 | 16135485 17606976 |
OMIM:609423 |
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO |
marker/mechanism |
|
| |
MESH:D007154 |
Immune System Diseases |
|
Cyclophosphamide |
5.77 | 16076520 |
MESH:D007248 |
Infertility, Male |
|
Cyclophosphamide |
3.79 | 7193160 16517039 |
MESH:D007249 |
Inflammation |
|
polyphenols |
3.18 | 16366677 |
MESH:D007333 |
Insulin Resistance |
|
Sodium Selenite |
3.45 | 14714311 |
MESH:D007938 |
Leukemia |
|
Cyclophosphamide |
3.61 | 10602166 |
MESH:D015451 |
Leukemia, Lymphocytic, Chronic, B-Cell |
|
Cyclophosphamide |
3.59 | 17296974 17658394 18587576 17802794 17008537 18172266 |
MESH:D015464 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
|
Cyclophosphamide |
4.29 | 10373061 |
MESH:D007970 |
Leukopenia |
|
Cyclophosphamide |
5.36 | 10052129 11830472 |
MESH:D008107 |
Liver Diseases |
|
polyphenols |
2.83 | 16698588 |
MESH:D008175 |
Lung Neoplasms |
|
vanadium pentoxide |
3.23 | 12376484 |
MESH:D008223 |
Lymphoma |
|
Cyclophosphamide |
4.03 | 12854902 |
MESH:D016393 |
Lymphoma, B-Cell |
|
Cyclophosphamide |
11.42 | 16675587 |
MESH:D016393 |
Lymphoma, B-Cell |
|
Sodium Selenite |
11.42 | 14737004 |
MESH:D008228 |
Lymphoma, Non-Hodgkin |
|
Cyclophosphamide |
4.40 | 11911406 |
MESH:D008268 |
Macular Degeneration |
marker/mechanism |
|
| |
MESH:D008546 |
Melanoma, Experimental |
|
Cyclophosphamide |
5.16 | 16388313 |
MESH:D009369 |
Neoplasms |
|
Cyclophosphamide |
3.24 | 18854779 |
MESH:D009447 |
Neuroblastoma |
|
Cyclophosphamide |
3.76 | 15176712 16115947 8761367 |
MESH:D017599 |
Neuroectodermal Tumors |
|
Cyclophosphamide |
5.28 | 12837982 8761367 |
MESH:D009503 |
Neutropenia |
|
Cyclophosphamide |
4.63 | 8291058 |
MESH:D009845 |
Oligospermia |
|
Cyclophosphamide |
5.11 | 16517039 |
MESH:D010146 |
Pain |
|
Cyclophosphamide |
3.85 | 12161096 18093676 |
MESH:D010190 |
Pancreatic Neoplasms |
|
Cyclophosphamide |
3.26 | 11332152 |
MESH:D054198 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
|
Cyclophosphamide |
3.94 | 21297632 |
MESH:D011471 |
Prostatic Neoplasms |
|
Cyclophosphamide |
3.51 | 17136230 |
MESH:D011471 |
Prostatic Neoplasms |
|
Sodium Selenite |
3.51 | 18760546 |
MESH:D011658 |
Pulmonary Fibrosis |
|
Cyclophosphamide |
3.37 | 16636934 |
MESH:D012595 |
Scleroderma, Systemic |
|
Cyclophosphamide |
5.13 | 16636934 |
OMIM:102530 |
SPERMATOGENIC FAILURE 6 |
|
Cyclophosphamide |
5.91 | 16517039 |
MESH:D015173 |
Supratentorial Neoplasms |
|
Cyclophosphamide |
5.45 | 12837982 |
MESH:D013705 |
Temporomandibular Joint Disorders |
|
polyphenols |
5.69 | 17997062 |
MESH:D001749 |
Urinary Bladder Neoplasms |
|
Cyclophosphamide |
3.23 | 14692829 |